6. Insulet Corporation (NASDAQ:PODD)
Stock Upside: 67.59%
Market Capitalization: $10.18 billion
Insulet Corporation (NASDAQ:PODD) ranks sixth among the most promising healthcare stocks according to Wall Street analysts, and its story is centered on one of the most important daily realities in chronic disease care: diabetes management. Trading at $145.76, with the stock up 1.56%, Insulet Corporation (NASDAQ) has a market capitalization of $10.18 billion, a stock upside of 67.59%, and 55 hedge fund holders as of Q1 2026. For investors searching for diabetes stocks, medical device stocks, insulin delivery stocks, healthcare technology stocks, and Wall Street healthcare stock picks, Insulet stands out because it is trying to make insulin therapy more automated, more flexible, and less dependent on constant manual decision-making.
On June 6, Insulet Corporation (NASDAQ) released new clinical results for two next-generation diabetes management systems: Omnipod 6 and a fully closed-loop system for type 2 diabetes. Management described the data as strong and said the results bring the company closer to turning those systems into commercial realities. That matters because diabetes care is one of the biggest markets in healthcare, but it is also one of the most demanding. Patients must constantly manage blood sugar, insulin dosing, meals, activity, and daily routine. Devices that reduce this burden can have major clinical and commercial importance.
The first study, called the STRIVE pivotal trial, compared the current Omnipod 5 system with Omnipod 6. The results showed that Omnipod 6 improved time in tight range by 7% for adults with type 1 diabetes and by 5% for patients with type 2 diabetes. Overall time in range also improved across both groups. For people outside diabetes care, “time in range” may sound technical, but it is one of the most important measures in modern glucose management. It refers to the amount of time a person’s blood sugar stays within the target range. More time in range generally means better glucose control and fewer highs and lows, which can affect long-term health and quality of life.
The STRIVE data also showed that Omnipod 6 delivered up to 50% more automated insulin. That is important because automated insulin delivery is one of the most meaningful advances in diabetes technology. The more a system can safely adjust insulin delivery on its own, the less burden falls on the patient. Another key finding was that Omnipod 6 performed better even when patients bolused less. In plain language, bolusing refers to manually dosing insulin, often around meals. One of the real-world challenges in diabetes management is that patients do not always remember, choose, or correctly calculate meal doses. Insulet said Omnipod 6 can help compensate for that gap, which could make it valuable for patients who struggle with consistency.
The second study, called EVOLUTION 3, tested the fully closed-loop system for type 2 diabetes. The results showed 64% time in range, a 12% improvement from baseline. The system also reduced total daily insulin from 86 units to 58 units without accompanying weight gain, and 86% of participants said they were satisfied or highly satisfied with the system. Those results are notable because type 2 diabetes is a massive treatment category, and insulin use in type 2 patients can be difficult to manage. A fully closed-loop system that improves glucose control while reducing total insulin use could become an important tool if future trials confirm the results and regulators eventually clear the device.
Insulet emphasized that both Omnipod 6 and the fully closed-loop system remain investigational and have not yet been cleared by the FDA. That detail is important. Investors should not treat these products as guaranteed commercial launches. Medical device development still requires additional studies, regulatory review, manufacturing readiness, and payer acceptance. However, the company has already enrolled the first patients in the next trial for the fully closed-loop system, called EVOLVE, and is targeting a commercial launch in 2028. That gives investors a clearer timeline to watch.
Insulet Corporation (NASDAQ) specializes in insulin delivery systems for people with diabetes, and its flagship product is the Omnipod insulin management system. The company’s appeal comes from the fact that it sits at the crossroads of medical devices, wearable technology, chronic disease care, and automated therapy. For investors looking for promising healthcare stocks, diabetes technology stocks, medical device stocks with upside, and healthcare stocks to buy now, Insulet has a story that is both practical and growth-oriented. Diabetes is not a niche problem. It is a massive global health issue, and products that make treatment easier can build strong demand over time.
With a 67.59% stock upside estimate and a $10.18 billion market capitalization, Insulet Corporation (NASDAQ) is one of the more compelling healthcare technology names in this ranking. It is not risk-free, especially because future product launches still depend on successful development and FDA clearance. But Wall Street analysts appear to see meaningful upside in the company’s next-generation systems. In a healthcare market where investors are looking for both innovation and real-world commercial relevance, Insulet offers a direct story: better diabetes management through smarter insulin delivery.
YOU MUST READ THIS: Top 10 Small-Cap Biotech Stocks That Could Surge 100%
Click here to continue reading and checkout the Top 5 Healthcare Stocks That Could Turn a $1,000 Investment Into Something Bigger.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
